AU2003282247A1 - Anti-activated ras antibodies - Google Patents

Anti-activated ras antibodies Download PDF

Info

Publication number
AU2003282247A1
AU2003282247A1 AU2003282247A AU2003282247A AU2003282247A1 AU 2003282247 A1 AU2003282247 A1 AU 2003282247A1 AU 2003282247 A AU2003282247 A AU 2003282247A AU 2003282247 A AU2003282247 A AU 2003282247A AU 2003282247 A1 AU2003282247 A1 AU 2003282247A1
Authority
AU
Australia
Prior art keywords
seq
antibody
ras
scfv
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003282247A
Other languages
English (en)
Inventor
Terence Howard Rabbitts
Tomoyuki Tanaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Council
Original Assignee
Medical Research Council
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0226723A external-priority patent/GB0226723D0/en
Priority claimed from GBGB0226729.2A external-priority patent/GB0226729D0/en
Priority claimed from GB0226728A external-priority patent/GB0226728D0/en
Priority claimed from GBGB0226727.6A external-priority patent/GB0226727D0/en
Priority claimed from GB0226731A external-priority patent/GB0226731D0/en
Priority claimed from GB0316680A external-priority patent/GB0316680D0/en
Application filed by Medical Research Council filed Critical Medical Research Council
Publication of AU2003282247A1 publication Critical patent/AU2003282247A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2003282247A 2002-11-15 2003-11-14 Anti-activated ras antibodies Abandoned AU2003282247A1 (en)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
GB0226723.5 2002-11-15
GB0226723A GB0226723D0 (en) 2002-11-15 2002-11-15 Antibodies for in vitro use
GB0226731.8 2002-11-15
GBGB0226729.2A GB0226729D0 (en) 2002-11-15 2002-11-15 Intracellular antibodies
GB0226727.6 2002-11-15
GB0226728A GB0226728D0 (en) 2002-11-15 2002-11-15 Anti-activated RAS antibodies
GB0226729.2 2002-11-15
GBGB0226727.6A GB0226727D0 (en) 2002-11-15 2002-11-15 Intrabodies
GB0226728.4 2002-11-15
GB0226731A GB0226731D0 (en) 2002-11-15 2002-11-15 Method for generating immunoglobulin genes
GB0316680A GB0316680D0 (en) 2003-07-16 2003-07-16 Anti-activated RAS antibodies
GB0316680.8 2003-07-16
PCT/GB2003/004953 WO2004046188A2 (en) 2002-11-15 2003-11-14 Anti-activated ras antibodies

Publications (1)

Publication Number Publication Date
AU2003282247A1 true AU2003282247A1 (en) 2004-06-15

Family

ID=32330172

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003282247A Abandoned AU2003282247A1 (en) 2002-11-15 2003-11-14 Anti-activated ras antibodies

Country Status (6)

Country Link
US (1) US20050288492A1 (cg-RX-API-DMAC10.html)
EP (1) EP1565495A2 (cg-RX-API-DMAC10.html)
JP (1) JP2006521088A (cg-RX-API-DMAC10.html)
AU (1) AU2003282247A1 (cg-RX-API-DMAC10.html)
CA (1) CA2506128A1 (cg-RX-API-DMAC10.html)
WO (1) WO2004046188A2 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2360255E (pt) 2005-03-25 2015-04-08 Nat Res Council Canada Método para isolamento de polipéptidos solúveis
EP1867661A1 (en) * 2006-06-12 2007-12-19 Diatos Compositions and methods for delivering anti-activated ras antibodies into cells
JP5172943B2 (ja) 2008-03-12 2013-03-27 パナソニック株式会社 無線通信装置、無線通信システム及び無線通信方法
AU2010238346A1 (en) * 2009-04-14 2011-11-03 Trojan Technologies Ltd. Therapeutic Antennapedia-antibody molecules and methods of use thereof
GB201103631D0 (en) * 2011-03-03 2011-04-13 Univ Leeds Identification of candidate therapeutics
HRP20201914T1 (hr) 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
KR101602876B1 (ko) 2014-07-22 2016-03-11 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용
KR101602870B1 (ko) 2014-07-22 2016-03-21 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 항체를 세포막을 투과하여 세포질에 위치시키는 방법 및 그의 이용
WO2016013871A1 (ko) * 2014-07-22 2016-01-28 아주대학교산학협력단 완전한 이뮤노글로불린 형태의 세포질 침투능을 갖는 항체를 이용하여 세포내 활성화된 ras를 억제하는 방법 및 그의 이용
MX2017006167A (es) 2014-11-12 2018-03-23 Siamab Therapeutics Inc Compuestos que interactúan con glicanos y métodos de uso.
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
JP2019520086A (ja) 2016-05-27 2019-07-18 オラム・セラピューティクス・インコーポレイテッド 細胞質浸透抗体およびその用途
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
KR20240044544A (ko) 2017-03-03 2024-04-04 씨젠 인크. 글리칸-상호작용 화합물 및 사용 방법
WO2019014190A1 (en) 2017-07-10 2019-01-17 Brown Kathlynn C MOLECULAR GUIDANCE SYSTEM PEPTIDES AND USES THEREOF
EP3652195A4 (en) 2017-07-10 2021-08-04 SRI International PEPTID-SAPORINE CONJUGATE FOR THE TREATMENT OF CANCER
KR20190143826A (ko) 2018-06-21 2019-12-31 오름테라퓨틱 주식회사 세포/조직 특이적 세포 침투 항체
GB202006974D0 (en) * 2020-05-12 2020-06-24 Univ Oxford Innovation Ltd Chimaeric proteins and therapeutic agents

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003219277A1 (en) * 2002-03-14 2003-09-29 Medical Research Council Intracellular antibodies

Also Published As

Publication number Publication date
WO2004046188A3 (en) 2004-09-16
EP1565495A2 (en) 2005-08-24
US20050288492A1 (en) 2005-12-29
CA2506128A1 (en) 2004-06-03
WO2004046188A2 (en) 2004-06-03
JP2006521088A (ja) 2006-09-21

Similar Documents

Publication Publication Date Title
CN108884160B (zh) 抗ror1抗体
US20050288492A1 (en) Anti-activated RAS antibodies
US20050276800A1 (en) Intrabodies
JP7663977B2 (ja) 抗ｐｄ―ｌ１抗体およびその用途
US20100143939A1 (en) Intracellular antibodies
WO2003077945A1 (en) Intracellular antibodies
US20180106790A1 (en) Single chain proteins with c-terminal modifications
AU2017260232B2 (en) Anti-Kv1.3 antibodies, and methods of production and use thereof
CN112442122B (zh) 阻断型pd-1纳米抗体及其编码序列和用途
US20250197481A1 (en) Antigen Binding Polypeptides, Antigen Binding Polypeptide Complexes and Methods of Use Thereof in HIV
CN113004416B (zh) 靶向her2-cd137双特异性抗体的构建及其应用
CN114751988B (zh) 中和冠状病毒的多特异性抗体
WO2004046187A2 (en) Antibodies for in vitro use
WO2024173565A2 (en) Human synthetic antibodies targeting human epidermal growth factor receptor 2 (her2) mutants
WO2024031049A2 (en) Pharmaceutical compositions of fusion proteins and methods of use thereof
CN103374072A (zh) 一种抗Mac-2BP人源化抗体的制备
Olsen Functional investigation of the EWS/ATF1 fusion protein: Implications for molecular therapy in clear cell sarcoma
CN103374071A (zh) 一种抗derlin-1人源化抗体的制备

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period